Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-benefits of vaccination programmes.

T Szucs1

  • 1Department of Medical Economics, University Hospital, Rämistrasse 100, CH-8091, Zurich, Switzerland.

Vaccine
|February 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear Astrophysics in the Storage Ring: Background Suppressed Simultaneous Measurement of (p,γ) and (p,n) Reactions.

Physical review letters·2025
Same author

First Direct Measurement of the 64.5 keV Resonance Strength in the ^{17}O(p,γ)^{18}F Reaction.

Physical review letters·2024
Same author

Proton-Capture Rates on Carbon Isotopes and Their Impact on the Astrophysical ^{12}C/^{13}C Ratio.

Physical review letters·2023
Same author

Direct Measurement of the ^{13}C(α,n)^{16}O Cross Section into the s-Process Gamow Peak.

Physical review letters·2021
Same author

The baryon density of the Universe from an improved rate of deuterium burning.

Nature·2020
Same author

Successful Prediction of Total α-Induced Reaction Cross Sections at Astrophysically Relevant Sub-Coulomb Energies Using a Novel Approach.

Physical review letters·2020
Same journal

Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.

Vaccine·2026
Same journal

Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.

Vaccine·2026
Same journal

Human systemic and mucosal immune responses support further exploration of a Klebsiella pneumoniae protein-based vaccine.

Vaccine·2026
Same journal

Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" [Vaccine 42(9) (2024) 2254-2259].

Vaccine·2026
Same journal

Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines.

Vaccine·2026
Same journal

Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025-2035.

Vaccine·2026
See all related articles

Economic evaluations like cost-benefit and cost-effectiveness analysis guide healthcare resource allocation. Cost-utility analysis, using quality-adjusted life years (QALYs), compares interventions, aiding vaccination program planning and vaccine decision-making.

Area of Science:

  • Health Economics
  • Public Health Policy
  • Vaccinology

Background:

  • Healthcare resource allocation demands robust economic data.
  • Key economic evaluation tools include cost-benefit, cost-effectiveness, and cost-utility analyses.
  • Cost-utility analysis utilizes quality-adjusted life years (QALYs) for broad intervention comparison.

Purpose of the Study:

  • To delineate the application of different economic evaluation methods in healthcare decision-making.
  • To explore the utility of cost-utility analysis for vaccination program planning.
  • To differentiate the optimal use of cost-benefit versus cost-effectiveness analysis for public health and recommended vaccines.

Main Methods:

  • Review and synthesis of economic evaluation methodologies.

Related Experiment Videos

  • Application of cost-utility analysis principles to vaccination programs.
  • Comparative analysis of cost-benefit and cost-effectiveness approaches for vaccine assessment.

    • Main Results:

    • Cost-effectiveness analysis aids in optimizing resource use within allocated budgets.
    • Cost-benefit analysis informs broader resource allocation decisions.
    • Cost-utility analysis, via QALYs, enables direct comparison of diverse medical interventions, including vaccinations.
    • Combinations of vaccines offer significant economic benefits through reduced costs and improved coverage.

    Conclusions:

    • Appropriate economic evaluation tools are crucial for effective healthcare resource allocation.
    • Cost-utility analysis is valuable for comparing childhood vaccinations and planning programs.
    • Public health vaccines benefit from cost-benefit analysis, while recommended vaccines are better suited for cost-effectiveness analysis.
    • Vaccination programs can achieve substantial cost-savings and economic advantages.